Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT

[1]  M. Labopin,et al.  Thiotepa‐based versus total body irradiation‐based myeloablative conditioning prior to allogeneic stem cell transplantation for acute myeloid leukaemia in first complete remission: a retrospective analysis from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantati , 2016, European journal of haematology.

[2]  S. Forman,et al.  Hematopoietic Cell Transplantation , 2015 .

[3]  H. Greinix,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease , 2015 .

[4]  Daniel Wolff,et al.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[5]  M. Labopin,et al.  Comparison of outcomes after single or double cord blood transplantation in adults with acute leukemia using different types of myeloablative conditioning regimen, a retrospective study on behalf of Eurocord and the Acute Leukemia Working Party of EBMT , 2014, Leukemia.

[6]  N. Kröger,et al.  Allogeneic hematopoietic SCT for adults AML using i.v. BU in the conditioning regimen: outcomes and risk factors for the occurrence of hepatic sinusoidal obstructive syndrome , 2014, Bone Marrow Transplantation.

[7]  M. Labopin,et al.  Allogeneic hematopoietic stem-cell transplantation for acute myeloid leukemia in remission: comparison of intravenous busulfan plus cyclophosphamide (Cy) versus total-body irradiation plus Cy as conditioning regimen--a report from the acute leukemia working party of the European group for blood and , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Solano,et al.  Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen , 2012, Bone Marrow Transplantation.

[9]  M. Díaz-Beyá,et al.  The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade. , 2011, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[10]  M. Mohty,et al.  Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update , 2011, Blood cancer journal.

[11]  Allen R. Chen,et al.  Hepatic veno-occlusive disease following stem cell transplantation: incidence, clinical course, and outcome. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[12]  M. Sanz,et al.  Cord blood transplantation from unrelated donors in adults with high-risk acute myeloid leukemia. , 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[13]  B. Sandmaier,et al.  Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. , 2009, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[14]  F. Appelbaum,et al.  Hematopoietic-cell transplantation at 50. , 2007, The New England journal of medicine.

[15]  A. Ibatici,et al.  Thiotepa-based reduced intensity conditioning regimen: a 10 year follow up , 2007, Bone Marrow Transplantation.

[16]  C. Mecucci,et al.  Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Turner,et al.  National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. , 2005, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[18]  M. Varettoni,et al.  Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies , 2004, Bone Marrow Transplantation.

[19]  C. Sigouin,et al.  Canadian multicenter pilot trial of haploidentical donor transplantation. , 2004, Blood cells, molecules & diseases.

[20]  Y. Nieto,et al.  Pharmacokinetics of high-dose chemotherapy , 2004, Bone Marrow Transplantation.

[21]  S. Rodenhuis,et al.  Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  A. Pileri,et al.  Reduced-intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. , 2002, Blood.

[23]  J. Wagner,et al.  Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. , 2001, The New England journal of medicine.

[24]  T. Lamparelli,et al.  Alternative donor transplants for patients with advanced hematologic malignancies, conditioned with thiotepa, cyclophosphamide and antithymocyte globulin , 2000, Bone Marrow Transplantation.

[25]  G. Jayson,et al.  Prospective evaluation of oral mucositis in patients receiving myeloablative conditioning regimens and haemopoietic progenitor rescue , 2000, British journal of haematology.

[26]  F. Frassoni,et al.  Reduced intensity thiotepa–cyclophosphamide conditioning for allogeneic haemopoietic stem cell transplants (HSCT) in patients up to 60 years of age , 2000, British journal of haematology.

[27]  A. Nagler,et al.  The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia. , 1999, Leukemia research.

[28]  R. Setroikromo,et al.  Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice , 1998, Bone Marrow Transplantation.

[29]  A. Nagler,et al.  Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation. , 1997, Blood.

[30]  E. Bayever,et al.  A study of thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. , 1996, Bone marrow transplantation.

[31]  S. Hanauer,et al.  Tandem high-dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. , 1996, Bone marrow transplantation.

[32]  F. Benvenuto,et al.  Thiotepa cyclophosphamide followed by granulocyte colony-stimulating factor mobilized allogeneic peripheral blood cells in adults with advanced leukemia. , 1996, Blood.

[33]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.

[34]  D. Waxman,et al.  N,N',N''-triethylenethiophosphoramide (thio-TEPA) oxygenation by constitutive hepatic P450 enzymes and modulation of drug metabolism and clearance in vivo by P450-inducing agents. , 1991, Cancer research.

[35]  F. Balis,et al.  Phase I and pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients: evidence for dose-dependent plasma clearance of thiotepa. , 1989, Cancer research.

[36]  Pankaj Sharma,et al.  Venocclusive Disease of the Liver after Bone Marrow Transplantation: Diagnosis, Incidence, and Predisposing Factors , 1984, Hepatology.

[37]  R. Nuscher,et al.  Bone marrow transplantation. , 1977, The American journal of nursing.

[38]  Emanuél' Nm,et al.  Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs. , 1976 .

[39]  N. Konovalova,et al.  Toxicity, antitumor activity, and pharmacokinetics of spin-labeled thioTEPA analogs. , 1976, Cancer treatment reports.